BPC-157
Pentadecapeptide derived from a gastric protein. Promoted for tendon/ligament repair and GI healing. No FDA approval; FDA placed on Category 2 compounding list.
At a glance
- Common vial size
- 5 mg
- Reference dose
- 250 mcg
- Frequency
- 1–2× daily
Reference titration protocol
200 → 400 → 600 mcg, step every 2 weeks, once daily.
| Step | Dose | Duration | Administrations / week |
|---|---|---|---|
| 1 | 200 mcg | 2 weeks | 7× |
| 2 | 400 mcg | 2 weeks | 7× |
| 3 | 600 mcg | 2 weeks | 7× |
A 5 mg vial reconstituted with 3 mL of bacteriostatic water yields 1.667 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.
Open this configuration in the calculatorClinical notes
- Human clinical data limited
- FDA 503A bulk substance: not nominated
Available formulations
Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.
- 0 · Lyophilized PowderR&D
- 0 · Nasal StripsR&D
- 0 · Pen503B
- 10 ml · Injectable503A
- Capsule/TabletR&D
- Capsule/Tablet503A
- Capsules503A
- Injectable503A
- Lyophilized PowderR&D
- Nasal Spray503A
- Nasal StripsR&D
Pricing and ordering are for verified accounts
VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.
